Research ExplorerPublicationsRadiation therapy compared to radical prostatectomy as first...

Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis

Standard

Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis. / Aydh, Abdulmajeed; Motlagh, Reza Sari; Abufaraj, Mohammad; Mori, Keiichiro; Katayama, Satoshi; Grossmann, Nico; Rajwa, Pawel; Mostafai, Hadi; Laukhtina, Ekaterina; Pradere, Benjamin; Quhal, Fahad; Schuettfort, Victor M; Briganti, Alberto; Karakiewicz, Pierre I; Fajkovic, Haron; Shariat, Shahrokh F.

In: ARAB J UROL, Vol. 20, No. 2, 2022, p. 71-80.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Aydh, A, Motlagh, RS, Abufaraj, M, Mori, K, Katayama, S, Grossmann, N, Rajwa, P, Mostafai, H, Laukhtina, E, Pradere, B, Quhal, F, Schuettfort, VM, Briganti, A, Karakiewicz, PI, Fajkovic, H & Shariat, SF 2022, 'Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis', ARAB J UROL, vol. 20, no. 2, pp. 71-80. https://doi.org/10.1080/2090598X.2022.2026010

APA

Aydh, A., Motlagh, R. S., Abufaraj, M., Mori, K., Katayama, S., Grossmann, N., Rajwa, P., Mostafai, H., Laukhtina, E., Pradere, B., Quhal, F., Schuettfort, V. M., Briganti, A., Karakiewicz, P. I., Fajkovic, H., & Shariat, S. F. (2022). Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis. ARAB J UROL, 20(2), 71-80. https://doi.org/10.1080/2090598X.2022.2026010

Vancouver

Aydh A, Motlagh RS, Abufaraj M, Mori K, Katayama S, Grossmann N et al. Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis. ARAB J UROL. 2022;20(2):71-80. https://doi.org/10.1080/2090598X.2022.2026010

Bibtex

@article{0ac49b4ca8fe4d6d8f6010bea15f8749,
title = "Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis",
abstract = "OBJECTIVE: To present an update of the available literature on external beam radiation therapy (EBRT) with or without brachytherapy (BT) compared to radical prostatectomy (RP) for patients with high-risk localised prostate cancer (PCa).METHODS: We conducted a systematic review and meta-analysis of the literature assessing the survival outcomes in patients with high-risk PCa who received EBRT with or without BT compared to RP as the first-line therapy with curative intent. We queried PubMed and Web of Science database in January 2021. Moreover, we used random or fixed-effects meta-analytical models in the presence or absence of heterogeneity per the I2 statistic, respectively. We performed six meta-analyses for overall survival (OS) and cancer-specific survival (CSS).RESULTS: A total of 27 studies were selected with 23 studies being eligible for both OS and CSS. EBRT alone had a significantly worse OS and CSS compared to RP (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.16-1.65; and HR 1.55, 95% CI 1.25-1.93). However, there was no difference in OS (HR 1.1, 95% CI 0.76-1.34) and CSS (HR 0.69, 95% CI 0.45-1.06) between EBRT plus BT compared to RP.CONCLUSION: While cancer control affected by EBRT alone seems inferior to RP in patients with high-risk PCa, BT additive to EBRT was not different from RP. These data support the need for BT in addition to EBRT as part of multimodal RT for high-risk PCa.Abbreviations: ADT: androgen-deprivation therapy; BT: brachytherapy; CSS: cancer-specific survival; HR: hazard ratio; MFS, metastatic-free survival; MOOSE: Meta-analyses of Observational Studies in Epidemiology; OR: odds ratio; OS: overall survival; PCa: prostate cancer; RR: relative risk; RP: radical prostatectomy; RCT: randomised controlled trials; (EB)RT: (external beam) radiation therapy.",
author = "Abdulmajeed Aydh and Motlagh, {Reza Sari} and Mohammad Abufaraj and Keiichiro Mori and Satoshi Katayama and Nico Grossmann and Pawel Rajwa and Hadi Mostafai and Ekaterina Laukhtina and Benjamin Pradere and Fahad Quhal and Schuettfort, {Victor M} and Alberto Briganti and Karakiewicz, {Pierre I} and Haron Fajkovic and Shariat, {Shahrokh F}",
note = "{\textcopyright} 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",
year = "2022",
doi = "10.1080/2090598X.2022.2026010",
language = "English",
volume = "20",
pages = "71--80",
journal = "ARAB J UROL",
issn = "2090-598X",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis

AU - Aydh, Abdulmajeed

AU - Motlagh, Reza Sari

AU - Abufaraj, Mohammad

AU - Mori, Keiichiro

AU - Katayama, Satoshi

AU - Grossmann, Nico

AU - Rajwa, Pawel

AU - Mostafai, Hadi

AU - Laukhtina, Ekaterina

AU - Pradere, Benjamin

AU - Quhal, Fahad

AU - Schuettfort, Victor M

AU - Briganti, Alberto

AU - Karakiewicz, Pierre I

AU - Fajkovic, Haron

AU - Shariat, Shahrokh F

N1 - © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

PY - 2022

Y1 - 2022

N2 - OBJECTIVE: To present an update of the available literature on external beam radiation therapy (EBRT) with or without brachytherapy (BT) compared to radical prostatectomy (RP) for patients with high-risk localised prostate cancer (PCa).METHODS: We conducted a systematic review and meta-analysis of the literature assessing the survival outcomes in patients with high-risk PCa who received EBRT with or without BT compared to RP as the first-line therapy with curative intent. We queried PubMed and Web of Science database in January 2021. Moreover, we used random or fixed-effects meta-analytical models in the presence or absence of heterogeneity per the I2 statistic, respectively. We performed six meta-analyses for overall survival (OS) and cancer-specific survival (CSS).RESULTS: A total of 27 studies were selected with 23 studies being eligible for both OS and CSS. EBRT alone had a significantly worse OS and CSS compared to RP (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.16-1.65; and HR 1.55, 95% CI 1.25-1.93). However, there was no difference in OS (HR 1.1, 95% CI 0.76-1.34) and CSS (HR 0.69, 95% CI 0.45-1.06) between EBRT plus BT compared to RP.CONCLUSION: While cancer control affected by EBRT alone seems inferior to RP in patients with high-risk PCa, BT additive to EBRT was not different from RP. These data support the need for BT in addition to EBRT as part of multimodal RT for high-risk PCa.Abbreviations: ADT: androgen-deprivation therapy; BT: brachytherapy; CSS: cancer-specific survival; HR: hazard ratio; MFS, metastatic-free survival; MOOSE: Meta-analyses of Observational Studies in Epidemiology; OR: odds ratio; OS: overall survival; PCa: prostate cancer; RR: relative risk; RP: radical prostatectomy; RCT: randomised controlled trials; (EB)RT: (external beam) radiation therapy.

AB - OBJECTIVE: To present an update of the available literature on external beam radiation therapy (EBRT) with or without brachytherapy (BT) compared to radical prostatectomy (RP) for patients with high-risk localised prostate cancer (PCa).METHODS: We conducted a systematic review and meta-analysis of the literature assessing the survival outcomes in patients with high-risk PCa who received EBRT with or without BT compared to RP as the first-line therapy with curative intent. We queried PubMed and Web of Science database in January 2021. Moreover, we used random or fixed-effects meta-analytical models in the presence or absence of heterogeneity per the I2 statistic, respectively. We performed six meta-analyses for overall survival (OS) and cancer-specific survival (CSS).RESULTS: A total of 27 studies were selected with 23 studies being eligible for both OS and CSS. EBRT alone had a significantly worse OS and CSS compared to RP (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.16-1.65; and HR 1.55, 95% CI 1.25-1.93). However, there was no difference in OS (HR 1.1, 95% CI 0.76-1.34) and CSS (HR 0.69, 95% CI 0.45-1.06) between EBRT plus BT compared to RP.CONCLUSION: While cancer control affected by EBRT alone seems inferior to RP in patients with high-risk PCa, BT additive to EBRT was not different from RP. These data support the need for BT in addition to EBRT as part of multimodal RT for high-risk PCa.Abbreviations: ADT: androgen-deprivation therapy; BT: brachytherapy; CSS: cancer-specific survival; HR: hazard ratio; MFS, metastatic-free survival; MOOSE: Meta-analyses of Observational Studies in Epidemiology; OR: odds ratio; OS: overall survival; PCa: prostate cancer; RR: relative risk; RP: radical prostatectomy; RCT: randomised controlled trials; (EB)RT: (external beam) radiation therapy.

U2 - 10.1080/2090598X.2022.2026010

DO - 10.1080/2090598X.2022.2026010

M3 - SCORING: Review article

C2 - 35530569

VL - 20

SP - 71

EP - 80

JO - ARAB J UROL

JF - ARAB J UROL

SN - 2090-598X

IS - 2

ER -